Qualifying Therapeutic Discovery Project Grants for the State of Connecticut
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| Achillion Pharmaceuticals, Inc. | ACH-2881 | $ 166,432.50 | $ 78,046.75 |
| Achillion Pharmaceuticals, Inc. | ACH-1625 | $ 244,479.25 | |
| Achillion Pharmaceuticals, Inc. | ACH-2684 | $ 244,479.25 | |
| Achillion Pharmaceuticals, Inc. | Elvucitabine | $ 131,052.00 | $ 113,427.25 |
| Achillion Pharmaceuticals, Inc. | ACH-2928 | $ 244,479.25 | |
| Achillion Pharmaceuticals, Inc. | ACH-1095 | $ 244,479.25 | |
| Achillion Pharmaceuticals, Inc. | ACH-702 | $ 244,479.25 | |
| Achillion Pharmaceutics, Inc. | ACH-2892 | $ 244,479.25 | |
| AllerQuest, LLC | Penicillin Minor Determinants (PMD) | $ 244,479.24 | |
| AllerQuest, LLC | PrePen | $ 51,598.50 | |
| AMARIN PHARMACEUTICALS, INC. | AMR101 | $ 244,479.25 | |
| Applied Spine Technologies, Inc | Stabilimax Spine Stabilization System | $ 244,479.24 | |
| Artificial Cell Technologies | Nanoparticulate Vaccine Against Respiratory Syncytial Virus | $ 244,479.25 | |
| Axerion Therapeutics | Nogo receptor (NgR)protein therapy to treat chronic spinal cord injury | $ 244,479.25 | |
| Axerion Therapeutics | Cellular Prion Protein (PrP) as a treatment for Alzheimer's Disease | $ 122,818.50 | |
| Beta Pharma, Inc | Icotinib, a novel drug for the treatment of EGFR-mutated cancer diseases. | $ 87,192.09 | $ 157,287.16 |
| Biodel Inc | Smart Basal | $ 244,479.25 | |
| Biodel, Inc | VIAject | $ 244,479.25 | |
| Biodel, Inc. | Improved Glargine | $ 244,479.25 | |
| Biodel, Inc. | Glucagon | $ 244,479.25 | |
| Biodel, Inc. | VIAtab | $ 244,479.25 | |
| Biomedisyn Corporation | Huperzine for the Treatment of Schizophrenia | $ 21,405.80 | $ 137,070.98 |
| BioRelix, Inc. | Novel riboswitch-targeting treatments for multi-drug resistanr and hypervirulent bacteria | $ 244,479.24 | |
| Biowave Corporation | Prescription Peripheral Neuromodulation Pain System | $ 48,055.00 | $ 95,700.00 |
| Brain Tunnelgenix Technologies Corp | Discovery of the Brain Temperature Tunnel ( BTT) and the world's first non-invasive brain temperature monitoring device | $ 244,479.24 | |
| Cara Therapeutics Inc | Development of A Novel Analgesic, CR845 | $ 244,479.24 | |
| CAS Medical Systems Inc | Non-Invasive Cerebral/Tissue Oximetry | $ 244,479.25 | |
| Cheminpharma LLC | MEK Inhibitor for Treatment of Cancer | $ 59,362.50 | |
| Cytogel Pharma, LLC | Cyt-1010 | $ 244,479.24 | |
| CyVek, Inc (FKA CyVek, LLC) | CyVek: Enabling Proteomics | $ 21,281.00 | $ 223,198.25 |
| Genomas, Inc | PhyzioType System:Improve Treatment Outcome of Drugs for Mental Illness & Heart Disease | $ 156,399.00 | $ 88,080.24 |
| HistoRx Inc | AQUA technology Dianostics Enabling Better Treatment Decision | $ 244,479.25 | |
| Ikonisys Inc | OncoFISH cervical test | $ 244,479.24 | |
| IVFonline.com DBA Zenith Biotech, LLC | Develop and make liver biomatrix for extended hepatocyte functionality for drug discovery | $ 81,500.00 | $ 63,000.00 |
| IVFonline.com DBA Zenith Biotech, LLC | Novel Predictive Model for Hepatocytes Toxicity in Preclinical Drug Screening | $ 95,000.00 | $ 107,500.00 |
| IVFonline.com DBA Zenith Biotech, LLC. | Scalable Human Neural Stem Cells for High Throughput Screening | $ 122,500.00 | $ 118,000.00 |
| Kolltan Pharmaceuticals, Inc | RTK Project No. 5 | $ 244,479.25 | |
| Kolltan Pharmaceuticals, Inc | RTK Project No.4 | $ 244,479.25 | |
| Kolltan Pharmaceuticals, Inc | RTK Project No.3 | $ 244,479.25 | |
| Kolltan Pharmaceuticals, Inc. | RTK Project No. 1 | $ 244,479.25 | |
| Kolltan Pharmaceuticals, Inc. | RTK Project No. 2 | $ 244,479.25 | |
| Kolltan Pharmaceuticals, Inc. | RTK Project No. 6 | $ 244,479.25 | |
| Kotinos Pharmaceuticals Inc | Development of Tigapotide (PCK3145) as novel therapy for prostate cancer | $ 196,017.00 | $ 48,462.24 |
| Marinus Pharmaceuticals Inc. | Ganaxolone for Adjunctive Treatment of Partial Onset Seizures | $ 244,479.25 | |
| Marinus Pharmaceuticals Inc. | Ganaxolone for Treatment of Posttraumatic Stress Disorder (PTSD) | $ 244,479.25 | |
| MEDADHERENCE LLC | DIABETES REMOTE MANAGEMENT SYSTEM | $ 244,479.25 | |
| Molecular Neuroimaging LLC | Biomarkers for the Diagnosis of Parkinson's Disease | $ 222,854.00 | $ 21,625.25 |
| Molecular Neuroimaging LLC | Biomarkers for the Diagnosis of Alzheimer Disease | $ 202,974.50 | $ 41,504.75 |
| Myometrics, LLC | A small molecule agonist for enhancing alvelolar bone regeneration in toothextraction | $ 10,043.50 | $ 1,230.50 |
| Optherion, Inc | rhCFHp - Recombinant Human Factor H | $ 244,479.24 | |
| Protein Sciences Corporation | FluBlok | $ 244,479.25 | |
| Protein Sciences Corporation | PanBlok | $ 244,479.25 | |
| RIB-X PHARMACEUTICALS INC | RX-04 Completely New Antibiotics to Treat Multi-drug Resistant Infections | $ 244,479.25 | |
| RIB-X PHARMACEUTICALS, INC. | Delafloxacin: a broad spectrum antibiotic for the treatment of multi-drug resistant infections | $ 244,479.25 | |
| RIB-X PHARMACEUTICALS, INC. | RX-02: Enhanced Marcrolides for Treating Drug-Resistant Community Infections | $ 244,479.25 | |
| RIB-X PHARMACEUTICALS, INC. | Radezolid: A Novel Oxazolidinone Antibiotic for Resistant Gram-positive Infections | $ 244,479.25 | |
| Sibtech Inc | Guiding Cancer Therapy by imaging VEGF Receptors | $ 244,479.25 | |
| SurgiQuest, Inc. | AirSeal ® Trocar & Cannula System | $ 244,479.25 | |
| The Bronx Project Inc | The Bronx Project | $ 26,739.00 | $ 217,740.25 |
| The Institutes for Pharmaceutical Discovery LLC | Arginase Inhibitor Program | $ 244,479.24 | |
| The Institutes for Pharmaceutical Discovery LLV | Urinary Peptide Assay | $ 244,479.24 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
